TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9754848

Group type: EXPERIMENTAL
Intervention: 50 mg tolperisone hydrochloride
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 150 mg tolperisone hydrochloride
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 8850405

Group type: EXPERIMENTAL
Intervention: Nifedipine (group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 34
Study: 2651226

Group type: EXPERIMENTAL
Intervention: Surgical anterior oesophagomyotomy by abdominal route
Number of subjects: 81

Group type: COMPARATOR
Intervention: Pneumatic dilatation with the Mosher bag
Number of subjects: 81
Study: 579654

Group type: EXPERIMENTAL
Intervention: Holoxan therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 47
Study: 30221615

Group type: EXPERIMENTAL
Intervention: DREAMS-START intervention (six-session manualized therapy)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: DREAMS-START intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Treatment as Usual (control)
Number of subjects: 95
Study: 27558500

Group type: EXPERIMENTAL
Intervention: online behavioural training (oBT)
Number of subjects: 178

Group type: COMPARATOR
Intervention: watchful waiting (control group)
Number of subjects: 178
Study: 26270953

Group type: EXPERIMENTAL
Intervention: PARO (robotic animal)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Plush‐Toy (non‐robotic PARO)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: PARO or Plush‐Toy
Number of subjects: 380
Study: 24033650

Group type: EXPERIMENTAL
Intervention: Computerized aphasia therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 21876444

Group type: EXPERIMENTAL
Intervention: Crushed lopinavir/ritonavir tablets (200/50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Whole lopinavir/ritonavir tablets (200/50 mg)
Number of subjects: 12
Study: 19682886

Group type: EXPERIMENTAL
Intervention: CSE analgesia with bupivacaine 2.5mg and fentanyl 15 microg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intravenous fentanyl 50 microg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CSE analgesia
Number of subjects: 96

Group type: COMPARATOR
Intervention: SYS group (Intravenous fentanyl 50 microg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: SYS analgesia
Number of subjects: 96
Study: 16939523

Group type: EXPERIMENTAL
Intervention: PEG‐Intron 3‐6 microg kg(‐1) administered subcutaneously once a week
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: PEG‐Intron 6.0 microg kg(‐1) week(‐1)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: PEG‐Intron in patients with CML
Number of subjects: 137
Study: 15472204

Group type: EXPERIMENTAL
Intervention: Canrenoate (200 mg injections)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11576570

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Norethindrone-containing pills
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing pills
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no hormonal contraception)
Number of subjects: 155
Study: 9755734

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 369
Study: 7529657

Group type: EXPERIMENTAL
Intervention: Mast cell counts in osteoporotic individuals
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mast cell counts in normal individuals
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Proportion of ovoid mast cells in osteoporotic individuals
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mast cell counts in systemic mastocytosis
Number of subjects: 24
Study: 3503390

Group type: EXPERIMENTAL
Intervention: Intradermal injection of OK-432 (ID Group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of OK-432 (IM Group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (C Group)
Number of subjects: 121
Study: 31388792

Group type: EXPERIMENTAL
Intervention: AT-101 (40 mg) every 12 h on days 1, 2, and 3 combined with paclitaxel (150 mg/m2) and carboplatin (AUC 5) at DL1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AT-101 (40 mg) every 12 h on days 1, 2, and 3 combined with paclitaxel (175 mg/m2) and carboplatin (AUC 6) at DL2
Number of subjects: 24
Study: 29398304

Group type: EXPERIMENTAL
Intervention: Interactive Therapeutic Play Education Program
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 28838582

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Community care (COM)
Number of subjects: 39
Study: 26607848

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg total: two 40 mg capsules 1 hour prior to extraction and one 40 mg capsule postoperatively)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg total)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 24047916

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet (≥90 g protein/d)
Number of subjects: 323
Study: 21493931

Group type: EXPERIMENTAL
Intervention: Malawi Male Motivator intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 400
Study: 19515530

Group type: EXPERIMENTAL
Intervention: 1% ISDN in Vaseline applied to the dorsum of the affected hand four times daily for 10 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo ointment applied to the dorsum of the affected hand four times daily for 10 weeks
Number of subjects: 24
Study: 16826385

Group type: EXPERIMENTAL
Intervention: Standard CPR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Backboard CPR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kneeling on the bed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowering bed height
Number of subjects: 0
Study: 15220683

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors, H2‐receptor antagonists, prokinetics, or antacids (specifics not detailed)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Diagnostic procedures (specifics not detailed)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Therapy with proton pump inhibitors, H2‐receptor antagonists, prokinetics, or antacids
Number of subjects: 185
Study: 11069315

Group type: EXPERIMENTAL
Intervention: Conventional treatment for active ulcerative colitis
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Responders to treatment
Number of subjects: 25
Study: 9351415

Group type: EXPERIMENTAL
Intervention: Oral contraceptive users
Number of subjects: 819

Group type: COMPARATOR
Intervention: Non-users of oral contraceptives
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Athletes (both users and non-users)
Number of subjects: 819
Study: 1327630

Group type: EXPERIMENTAL
Intervention: Automated computerized program using Finapres for measuring cardiovascular reflexes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Automated computerized program using Finapres
Number of subjects: 10
Study: 2866830

Group type: EXPERIMENTAL
Intervention: Dezocine 10 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Dezocine 15 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Dezocine 5 mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 30548692

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day plus solifenacin 5 mg, propiverine 20 mg, imidafenacin 0.2 mg, or tolterodine 4 mg (with potential to double the antimuscarinic dose at week 8)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day plus antimuscarinic therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day plus propiverine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day plus tolterodine
Number of subjects: 100
Study: 29450494

Group type: EXPERIMENTAL
Intervention: ROR (Oncotype Dx recurrence score)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: BCI (Breast Cancer Index)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: EPclin (EndoPredict)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Clinical Treatment Score
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Recurrence score (Oncotype Dx)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: 4-marker immunohistochemical score
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: BCI (Breast Cancer Index) for patients with 1 to 3 positive nodes
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: EPclin (EndoPredict) for patients with 1 to 3 positive nodes
Number of subjects: 774
Study: 26714439

Group type: EXPERIMENTAL
Intervention: Fermented green tea
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (hot water)
Number of subjects: 60
Study: 24568917

Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 42
Study: 21751267

Group type: EXPERIMENTAL
Intervention: Soya milk intervention for 5 days
Number of subjects: 40
Study: 19558724

Group type: EXPERIMENTAL
Intervention: Speed of processing treatment
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Memory treatment
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Reasoning treatment
Number of subjects: 1804

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 1804
Study: 17598717

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with epinephrine at 1:200 000
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study: 15225189

Group type: EXPERIMENTAL
Intervention: 600 micro g misoprostol sublingually
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 ml syntometrine intravenously
Number of subjects: 60
Study: 12237651

Group type: EXPERIMENTAL
Intervention: Idiopathic hematuria
Number of subjects: 4307

Group type: COMPARATOR
Intervention: No idiopathic hematuria (Control)
Number of subjects: 4307
Study: 9698276

Group type: EXPERIMENTAL
Intervention: Pectin-rich plant extract from Gossypium herbaceum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7641723

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 2681086

Group type: EXPERIMENTAL
Intervention: Anandron 300 mg daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 999991

Group type: EXPERIMENTAL
Intervention: Passive hypnosis
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Suggested environmental conditions of cold and heat in hypnosis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Resting awake condition
Number of subjects: 2
Study: 30525956

Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter with misoprostol
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 1306
Study: 28946528

Group type: EXPERIMENTAL
Intervention: PNF treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manual therapy (MAN.T)
Number of subjects: 80
Study: 26401941

Group type: EXPERIMENTAL
Intervention: HIGH meal (50% total fat, 25% saturated fat, glycemic index >70)
Number of subjects: 46

Group type: COMPARATOR
Intervention: LOW meal (25% total fat, 7% saturated fat, glycemic index <55)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HIGH meal
Number of subjects: 46
Study: 23038624

Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21804104

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, 90 mg twice daily)
Number of subjects: 18421

Group type: COMPARATOR
Intervention: Clopidogrel (300-600 mg loading dose, 75 mg daily)
Number of subjects: 18421

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18421

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18421
Study: 19538732

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/day, orally, for 12 months)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 17055863

Group type: EXPERIMENTAL
Intervention: Pull sphincterotome
Number of subjects: 48

Group type: COMPARATOR
Intervention: Needle knife
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 12723673

Group type: EXPERIMENTAL
Intervention: Passive inversion and eversion movements at 0.1 degrees/s
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Passive inversion and eversion movements at 0.5 degrees/s
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Passive inversion and eversion movements at 2.5 degrees/s
Number of subjects: 69
Study: 10680098

Group type: EXPERIMENTAL
Intervention: Home-based (HB) exercise program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Center-based (CB)
Number of subjects: 31
Study: 9056681

Group type: EXPERIMENTAL
Intervention: Nisoldipine CC 10 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Nisoldipine CC 20 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Nisoldipine CC 30 mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 8338988

Group type: EXPERIMENTAL
Intervention: Soluble prednisolone + placebo inhalation + terbutaline inhalation
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Soluble placebo + budesonide inhalation + terbutaline inhalation
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Soluble placebo + placebo inhalation + terbutaline inhalation
Number of subjects: 123

Group type: COMPARATOR
Intervention: Soluble placebo + placebo inhalation + normal saline inhalation
Number of subjects: 123
Study: 2424238

Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.5 mg/kg body weight/day for 3 months)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.75 mg/kg for an additional 3 months)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.1 or 0 mg/kg during the second 3-month period)
Number of subjects: 90
Study: 31662976

Group type: EXPERIMENTAL
Intervention: Modified two-lobe technique
Number of subjects: 191
Study: 30133840

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Formula (Glucerna 1.5 kcal)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard Enteral Formula (Fresubin Energy Fibre)
Number of subjects: 107
Study: 27017161

Group type: EXPERIMENTAL
Intervention: EVARREST™ Fibrin Sealant Patch (FP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 102
Study: 24448120

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: OMP 2.5 mg dexamethasone on 2 consecutive days in a week
Number of subjects: 50
Study: 23271912

Group type: EXPERIMENTAL
Intervention: Microencapsulated CLA (3 g/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20359146

Group type: EXPERIMENTAL
Intervention: Penile injections
Number of subjects: 0
Study: 17329006

Group type: EXPERIMENTAL
Intervention: Experimental fluoride‐based toothpaste containing sodium hexametaphosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benchmark sodium fluoride paste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 0
Study: 12670128

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lithium chloride
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 10662743

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 to 40 mg/d)
Number of subjects: 6605

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6605
Study: 9376139

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 28
Study: 8335807

Group type: EXPERIMENTAL
Intervention: Direct coronary angioplasty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Streptokinase (1.2 million U intravenously over 1 h)
Number of subjects: 100
Study: 3552989

Group type: EXPERIMENTAL
Intervention: Killed whole Vibrio cholerae vaccine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Killed whole Vibrio cholerae vaccine with B subunit of cholera toxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Killed whole vibrio plus B subunit vaccine (preliminary data from field efficacy trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Killed whole vibrio vaccine alone (preliminary data from field efficacy trial)
Number of subjects: 0
Study: 30169575

Group type: EXPERIMENTAL
Intervention: Brief Intervention in Spanish (BI-S)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Brief Intervention in English (BI-E)
Number of subjects: 310
Study: 27522437

Group type: EXPERIMENTAL
Intervention: Cricopharyngeal dilation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Surgical myotomy
Number of subjects: 43
Study: 24590546

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate injection 25 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate injection 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate injection 150 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 22442277

Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified doogh (DD, containing 500 IU vitamin D(3) and 150 mg calcium/250 ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Calcium + vitamin D(3)-fortified doogh (CDD, containing 500 IU vitamin D(3) and 250 mg calcium/250 ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Plain Persian yogurt drink or doogh (PD, containing 150 mg calcium and no detectable vitamin D(3)/250 ml)
Number of subjects: 90
Study: 20457364

Group type: EXPERIMENTAL
Intervention: Standard coaxial phacoemulsification (2.8 mm incisions)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Microcoaxial phacoemulsification (2.2 mm incisions)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Biaxial microincision phacoemulsification (1.2 to 1.4 mm trapezoidal incisions)
Number of subjects: 135
Study: 18401017

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 274
Study: 15752181

Group type: EXPERIMENTAL
Intervention: Garlic (one visit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (the other visit)
Number of subjects: 0
Study: 12963898

Group type: EXPERIMENTAL
Intervention: Lymecycline 300 mg/day orally plus adapalene gel 0.1%
Number of subjects: 242

Group type: COMPARATOR
Intervention: Lymecycline 300 mg/day orally plus vehicle gel
Number of subjects: 242
Study: 10948685

Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 895

Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 895
Study: 8640382

Group type: COMPARATOR
Intervention: Heparin-aspirin therapy (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intermittent pulsatile pneumatic-pump compression of the plantar venous plexus (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both heparin-aspirin and intermittent compression (Group C)
Number of subjects: 75
Study: 1354494

Group type: EXPERIMENTAL
Intervention: Sodium heparin 5,000 IU injected into the abdominal wall
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sodium heparin 5,000 IU injected into the shoulder
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups (abdominal wall and shoulder)
Number of subjects: 101
Study: 6151364

Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 60
Study: 30617849

Group type: EXPERIMENTAL
Intervention: Self-initiated continuation of PrEP
Number of subjects: 84
Study: 30203767

Group type: EXPERIMENTAL
Intervention: Gatifloxacin eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levofloxacin (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 0
Study: 26986104

Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin combined with low caloric diet (n=115)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Insulin Glargine combined with Metformin (n=51)
Number of subjects: 166
Study: 24176681

Group type: EXPERIMENTAL
Intervention: Educational intervention (three educational sessions in small interactive groups)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 163
Study: 22082585

Group type: EXPERIMENTAL
Intervention: Argan oil (15 g/d) for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (habitual diet, no argan oil)
Number of subjects: 20
Study: 19015925

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 3818
Study: 17429539

Group type: COMPARATOR
Intervention: IFN‐alpha 1b 10 MU/m2 three times per week (Tiw)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN‐alpha 1b 10MU/m2 three times per week (Tiw) plus lamivudine 3 mg/kg for 6 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN‐alpha 1b 10 MU/m2 three times per week (Tiw) plus HBV vaccine 30 microg once a month
Number of subjects: 120
Study: 14523887

Group type: EXPERIMENTAL
Intervention: 60 mg intramuscular ketorolac
Number of subjects: 20
Study: 11144694

Group type: EXPERIMENTAL
Intervention: Bayesian model with severity of illness covariates
Number of subjects: 62

Group type: COMPARATOR
Intervention: General population model without covariates
Number of subjects: 62